Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Eculizumab in PNH
NCT00122317Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2005
- Primary completion
- Sep 2008
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoint: Incidence of Treatment-emergent Adverse Events at 2.5 years. Started May 2005; status: completed.
02
Drugs
eculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT00122317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122317.